Compare Merck & Co., Inc. (MRK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Otis Worldwide Corp — how do they compare? Merck & Co., Inc. trades at $146.16 (market cap $351.28B), while Otis Worldwide Corp trades at $66.35 (market cap $25.17B). The key difference: Merck & Co., Inc. is far larger — about 14× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Otis Worldwide Corp for 66 Days on average.
| MRK | OTIS | |
|---|---|---|
Market Cap | $351.28B | $25.17B |
Volume | 7,969,665 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $156.43 | $93.62 |
52-Week Low | $82.49 | $64.05 |
Typical Hold Time | 98 Days | 66 Days |
Enterprise Value | $398.04B | $33.20B |
Dividend Yield | 2.39% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Otis Worldwide trades at $66.14, up 0.61% today but near its 52-week low, with technical indicators showing bearish momentum. The company reported mixed Q2 2026 results, missing EPS estimates while maintaining strong service revenue growth. Recent CEO succession news and China market challenges create uncertainty, though analyst consensus remains positive with a $87 price target representing 31% upside potential.
The stock presents a value opportunity with reasonable P/E of 16.99 and P/S of 1.73, but faces margin pressure and execution risks. Service segment growth and modernization backlog provide stability, while weak equipment demand and China exposure remain headwinds. Institutional ownership shows mixed signals with recent buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
